The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxemia. Eur J Clin Invest.
Itoh H, Okamoto K. The mechanism behind coagulation disorders and organ dysfunction due to abdominal sepsis. J Abdomin Emerg Med. Google Scholar. Potential mechanism for a proinflammatory vascular cytokine response to coagulation activation. J Immunol. The proinflammatory cytokine response to coagulation and endotoxin in whole blood.
Esmon CT. Does inflammation contribute to thrombotic events? Cell biology of tissue factor, the principal initiator of blood coagulation. Macrophages and neutrophils infiltrating into the liver are responsible for tissue factor expression in a rabbit model of acute obstructive cholangitis. Thromb Haemost. Neutrophils express tissue factor in a monkey model of sepsis. Tissue factor in neutrophils: yes. Inhibition of factor Xa suppresses the expression of tissue factor in human monocytes and lipopolysaccharide induced endotoxemia in rats.
Lupu F. Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor. Am J Pathol. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. HMGB1 as a late mediator of lethal systemic inflammation.
HMG-1 as a late mediator of endotoxin lethality in mice. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. Proinflammatory cytokines tumor necrosis factor and interleukin 1 stimulate release of high mobility group protein-1 by pituicytes.
The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol. Ito T. Extracellular histones are major mediators of death in sepsis. Nat Med. Chaput C, Zychlinsky A. Sepsis: the dark side of histones. Endogenous histones function as alarmins in sterile inflammatory liver injury through Toll-like receptor 9 in mice. Circulating histones are mediators of trauma-associated lung injury. Extracellular DNA traps promote thrombosis.
Histones induce rapid and profound thrombocytopenia in mice. Inflammation, innate immunity and blood coagulation. Recombinant thrombomodulin protects mice against histone-induced lethal thromboembolism.
PLoS One. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.
Bibl Haematol. PubMed Google Scholar. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. SIRS-associated coagulopathy and organ dysfunction in critically ill patients with thrombocytopenia. Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation.
Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Frequency and hemostatic abnormalities in pre-DIC patients. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem. High-dose antithrombin in severe sepsis.
A randomized controlled trial. Vinazzer H. Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation. Semin Thromb Hemost. Clinical study of the therapeutic value of Kybernin in the treatment of antithrombin III deficiency.
Med Pregl. Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiol Scand. Double-blind, placebocontrolled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. High-dose antithrombin III treatment of severely injured patients: results of a prospective study.
J Trauma. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double blind trials with antithrombin III in severe sepsis. Intensive CareMed.
Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Wiedermann CJ, Kaneider N. A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis.
Blood Coagul Fibrinolysis. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a prospective multicenter survey. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis.
Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study. Clinical evaluation of low-molecular-weight heparin FR on disseminated intravascular coagulation DIC —a multicenter co-operative double-blind trial in comparison with heparin. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis.
Heparin therapy reduces day mortality in adult severe sepsis patients: a systematic review and meta-analysis. Heparins attenuated histone-mediated cytotoxicity in vitro and improved the survival in a rat model of histone-induced organ dysfunction.
Intensive Care Med Exp. Google Scholar. Jerrold H. Levy, M. Author and Article Information. Anesthesiology May , Vol. Get Permissions. View large Download slide. Table 1. View large. View Large. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism.
Search ADS. Epidemiology of disseminated intravascular coagulation in sepsis and validation of scoring systems. Inflammation and thrombosis: Roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis.
Role of extracellular vesicles in the development of sepsis-induced coagulopathy. Liaw PC. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Diagnosis of sepsis-induced disseminated intravascular coagulation and coagulopathy.
The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases. Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: The view from Japan.
Proposal of a two-step process for the diagnosis of sepsis-induced disseminated intravascular coagulation. Newly proposed sepsis-induced coagulopathy precedes international society on thrombosis and haemostasis overt-disseminated intravascular coagulation and predicts high mortality.
External validation of the two newly proposed criteria for assessing coagulopathy in sepsis. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Thrombotic thrombocytopenic purpura: Pathogenesis, diagnosis and potential novel therapeutics.
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. Laboratory testing for heparin-induced thrombocytopenia: A conceptual framework and implications for diagnosis. Potential diagnostic markers for disseminated intravascular coagulation of sepsis.
Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Septic shock, multiple organ failure, and disseminated intravascular coagulation: Compared patterns of antithrombin III, protein C, and protein S deficiencies. A general review of major global coagulation assays: Thrombelastography, thrombin generation test and clot waveform analysis.
Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: Results of an observational pilot study. Thromboelastography and rotational thromboelastometry for the surgical intensivist: A narrative review. Urinary glycosaminoglycans predict outcomes in septic shock and acute respiratory distress syndrome. Early detection of disseminated intravascular coagulation during septic shock: A multicenter prospective study.
Treatment effects of drotrecogin alfa activated in patients with severe sepsis with or without overt disseminated intravascular coagulation. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.
Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: An observational nationwide study. Antithrombin concentrate use in disseminated intravascular coagulation of sepsis: Meta-analyses revisited. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: The SCARLET randomized clinical trial. All Rights Reserved. View Metrics. Citing articles via Web Of Science Uptake of Halothane by the Human Body.
Email alerts Article Activity Alert. Coagulopathy of acute Sepsis. Semin Thromb Hemost. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. Changes in the blood coagulation system associated with septicemia.
The tissue factor pathway in disseminated intravascular coagulation. Nieman MT. Protease-activated receptors in hemostasis. Phosphatidylserine-mediated platelet clearance by endothelium decreases platelet aggregates and procoagulant activity in sepsis. Sci Rep. Levi M, van der Poll T. Coagulation and sepsis. Moake JL. Thrombotic microangiopathies.
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thromb J. The utility of a fast turnaround ADAMTS13 activity in the diagnosis and exclusion of thrombotic thrombocytopenic purpura. The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission.
Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers. Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. Expert Rev Hematol. Natural history of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan.
Caplacizumab for acquired thrombotic thrombocytopenic purpura. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol. Hemolytic uremic syndrome in children. Minerva Pediatr. Karmali MA. Factors in the emergence of serious human infections associated with highly pathogenic strains of shiga toxin-producing Escherichia coli.
Int J Med Microbiol. Emerging Shiga-toxin-producing Escherichia coli serogroup O80 associated hemolytic and uremic syndrome in France, differences with other serogroups. PLoS One. Shiga toxin Stx 1B and Stx2B induce von Willebrand factor secretion from human umbilical vein endothelial cells through different signaling pathways. Nat Rev Nephrol. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. Nephrol Dial Transplant.
Jokiranta TS. Update on Streptococcus pneumoniae associated hemolytic uremic syndrome. Curr Opin Pediatr. Streptococcus pneumoniae from patients with hemolytic uremic syndrome binds human plasminogen via the surface protein PspC and uses plasmin to damage human endothelial cells.
J Infect Dis. Expert statements on the standard of care in critically ill adult patients with atypical hemolytic uremic syndrome. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. Scully M, Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome.
Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolyticuremic syndrome. Clin Exp Nephrol.
Terminal complement inhibitor eculizumab in atypical hemolytic- uremic syndrome. Genetic testing of complement and coagulation pathways in patients with severe hypertension and renal microangiopathy. Mod Pathol. Thrombocytopenia in pregnancy. How we manage thrombotic microangiopathies in pregnancy. Erez O. Disseminated intravascular coagulation in pregnancy-clinical phenotypes and diagnostic scores.
Abildgaard U, Heimdal K. Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count HELLP : a review. Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets HELLP syndrome.
J Matern Fetal Neonatal Med. Acute fatty liver of pregnancy and concomitant medical conditions: a review of cases at a quaternary obstetric hospital.
Obstet Med. Treating acute fatty liver of pregnancy with artificial liver support therapy: Systematic review. A case report and systematic review. Clin Rheumatol. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence.
Rheumatol Int. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Ann Rheum Dis. Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. Clin Chem Lab Med. A systematic review. Catastrophic antiphospholipid syndrome: an update.
Panminerva Med. McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD. Bone Marrow Transplant. Transplant-associated thrombotic microangiopathy: opening Pandora's box. Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer.
J Oncol Pract. Izzedine H, Perazella MA. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis. Thrombotic microangiopathy and cancer. Nephrol Ther. VEGF inhibition and renal thrombotic microangiopathy. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature.
Am J Hematol. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol. Ther Apher Dial. Implications of the new international sepsis guidelines or nursing care.
Am J Crit Care. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Warkentin TE. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis.
Spontaneous HIT syndrome post-knee replacement surgery with delayed recovery of thrombocytopenia: a case report and literature review. Warkentin TE, Greinacher A. Management of heparin-induced thrombocytopenia. Autoimmune heparin-induced thrombocytopenia. Ischemic limb gangrene with pulses. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.
Liebman HA. Recognizing and treating secondary immune thrombocytopenic purpura associated with lymphoproliferative disorders. Semin Hematol. Immune thrombocytopenic purpura. Johnsen J. Pathogenesis in immune thrombocytopenia: new insights. Low platelet count as risk factor for infections in patients with primary immune thrombocytopenia: a retrospective evaluation.
Ann Hematol. Neunert CE, Cooper N. Evidence-based management of immune thrombocytopenia: ASH guideline update. International consensus report on the investigation and management of primary immune thrombocytopenia. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Recent advances in diagnostic and therapeutic guidelines for primary and secondary hemophagocytic lymphohistiocytosis. Blood Cells Mol Dis.
HLH diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. Article Google Scholar.
Secondary hemophagocytic lymphohistiocytosis in adults: an update on diagnosis and therapy. Clin Adv Hematol Oncol. Chalmers E. Purpura fulminans: recognition, diagnosis and management. Arch Dis Child.
0コメント